var data={"title":"Pyrazinamide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pyrazinamide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6876?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">see &quot;Pyrazinamide: Drug information&quot;</a> and <a href=\"topic.htm?path=pyrazinamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pyrazinamide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215773\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tebrazid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049590\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antitubercular Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049584\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">see &quot;Pyrazinamide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>N<b>ote:</b></b> Recommendations often change due to epidemiology (resistance) and emerging information; consult CDC and WHO for current recommendations, as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Active TB infection, treatment:</b> <b>Note:</b> Always use as part of a multidrug regimen. Any regimens using less than once daily dosing should administer dosing as directly observed therapy (DOT). Treatment regimens for pulmonary tuberculosis consist of an initial 2-month intensive phase of a 4-drug regimen, followed by a continuation phase of an additional 4 to 7 months of isoniazid and rifampin. Pyrazinamide frequency and dosing differs depending on treatment regimen selected; consult current drug-sensitive TB guidelines for detailed information (ATS/CDC/IDSA [Nahid 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ATS/CDC/IDSA Recommendations</i> (ATS/CDC/IDSA [Nahid 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Once daily or 5-times-weekly (DOT):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents weighing &lt;40 kg: Oral: 35 mg/kg/dose once daily or 5 times weekly DOT; suggested range: 30 to 40 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents weighing &ge;40 kg: <b>Note:</b> Doses should be based on <b>lean</b> body weight for patients within a normal weight range for their height (optimal dosing for obese patients has not been established): Oral: Weight-band dosing for whole tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">40 to 55 kg: 1,000 mg (18.2 to 25 mg/kg/dose) once daily or 5-times-weekly (DOT)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">56 to 75 kg: 1,500 mg (20 to 28.6 mg/kg/dose) once daily or 5-times-weekly (DOT)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">76 to 90 kg: 2,000 mg (22.2 to 26.3 mg/kg/dose) once daily or 5-times-weekly (DOT)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Three-times-weekly DOT: </i>\n      <b>Note:</b> Although suggested dosing based on experience with twice-weekly regimen; experts suggest three-times-weekly regimens are more effective than twice-weekly DOT regimens; pyrazinamide-containing three-times-weekly DOT may be used as part of an intensive phase; consult guidelines for specific information</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents weighing &lt;40 kg: Oral: 50 mg/kg/dose three times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents weighing &ge;40 kg:<b> Note: </b>Doses should be based on <b>lean</b> body weight for patients within a normal weight range for their height (optimal dosing for obese patients has not been established) Oral: Weight-band dosing for whole tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">40 to 55 kg: 1,500 mg (27.3 to 37.5 mg/kg/dose) three-times-weekly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">56 to 75 kg: 2,500 mg (33.3 to 44.6 mg/kg/dose) three-times-weekly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">76 to 90 kg: 3,000 mg (33.3 to 39.5 mg/kg/dose) three-times-weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Twice-weekly DOT: </i>\n      <b>Note:</b> Regimen not generally recommended; do not use in HIV patients or those with smear-positive and/or cavitary disease. This therapy should only be used following completion of a 2-week intensive phase once-daily (or 5-times-weekly) regimen. Missed doses result in the equivalent of once-weekly dosing which has been shown to be inferior and is associated with treatment failure, relapse, and development of drug resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents weighing &lt;40 kg: Oral: 50 mg/kg/dose twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents weighing &gt;40 kg: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">40 to 55 kg: 2,000 mg (36.4 to 50 mg/kg/dose) twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">56 to 75 kg: 3,000 mg (40 to 53.6 mg/kg/dose) twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">76 to 90 kg: 4,000 mg (44.4 to 52.6 mg/kg/dose) twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Tuberculosis treatment:</b> Oral: <b>Note:</b> Used as part of a multidrug regimen. Treatment regimens consist of an initial 2-month phase, followed by a continuation phase of 4 or 7 additional months; pyrazinamide is administered in the initial phase of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suggested dosing based on lean body weight (Blumberg 2003; CDC 2003):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Daily therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">40 to 55 kg: 1,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">56 to 75 kg: 1,500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">76 to 90 kg: 2,000 mg (maximum dose regardless of weight)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Twice weekly directly observed therapy (DOT):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">40 to 55 kg: 2,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">56 to 75 kg: 3,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">76 to 90 kg: 4,000 mg (maximum dose regardless of weight)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Three times/week DOT:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">40 to 55 kg: 1,500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">56 to 75 kg: 2,500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">76 to 90 kg: 3,000 mg (maximum dose regardless of weight)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b> Adults: Oral: CrCl &lt;30 mL/minute or receiving intermittent hemodialysis: 25 to 35 mg/kg/dose 3 times per week administered after dialysis (do not administer daily) (ATS/CDC/IDSA [Nahid 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use is contraindicated in cases of severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520318\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215737\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49913580\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May take without regard to food</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12736344\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049592\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunctive treatment of <i>Mycobacterium</i> tuberculosis infection in combination with other antituberculosis agents (FDA approved in children and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215814\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Malaise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acne vulgaris, acquired blood coagulation disorder (anticoagulant effect), angioedema (rare), dysuria, fever, gout, hepatotoxicity, interstitial nephritis, porphyria, pruritus, sideroblastic anemia, skin photosensitivity, skin rash, thrombocytopenia, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215759\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pyrazinamide or any component of the formulation; acute gout; severe hepatic damage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215741\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: Dose-related hepatotoxicity ranging from transient ALT/AST elevations to jaundice, hepatitis and/or liver atrophy (rare) has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Alcoholism: Due to concerns for preexisting hepatic dysfunction, use with caution in patients with a history of alcoholism (even if ethanol consumption is discontinued during therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gout: May inhibit uric acid excretion; acute gouty attacks have been reported. Use with caution in patients with chronic gout; contraindicated with acute gout.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Porphyria: Use with caution in patients with porphyria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal failure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxic agents: Use with caution in patients receiving concurrent medications associated with hepatotoxicity (particularly with rifampin). The 2-month rifampin-pyrazinamide regimen for the treatment of latent tuberculosis infection (LTBI) has been associated with severe and fatal liver injuries; incidence increased with pyrazinamide doses &gt;30 mg/kg/day. The Infectious Diseases Society of America and Centers for Disease Control and Prevention recommend that the 2-month rifampin-pyrazinamide regimen should not generally be used in patients with LTBI.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299964\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215746\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12751&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzbromarone: Pyrazinamide may diminish the therapeutic effect of Benzbromarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Pyrazinamide may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: Pyrazinamide may enhance the hepatotoxic effect of RifAMPin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215748\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13375012\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Due to the risk of tuberculosis to the fetus, treatment is recommended when the probability of maternal disease is moderate to high. Drug-susceptible TB guidelines recommend pyrazinamide as part of the initial treatment regimen; however, risks and benefits of use during pregnancy should be considered for each individual patient (Nahid 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049589\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic liver function tests, serum uric acid</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215740\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Converted to pyrazinoic acid in susceptible strains of <i>Mycobacterium</i> which lowers the pH of the environment; exact mechanism of action has not been elucidated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215758\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Bacteriostatic or bactericidal depending on drug's concentration at infection site </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Absorption: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely into body tissues and fluids including liver, lung, and CSF </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relative diffusion from blood into CSF: Adequate with or without inflammation (exceeds usual MICs) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF:blood level ratio: Inflamed meninges: 100% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 50% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 9 to 10 hours, prolonged with reduced renal or hepatic function</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Within 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (4% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215757\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>100 mg/mL Oral Suspension (ASHP Standard Concentration) (ASHP 2017)</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 100 mg/mL oral suspension may be made with tablets. Crush two-hundred pyrazinamide 500 mg tablets and mix with a suspension containing 500 mL methylcellulose 1% and 500 mL simple syrup. Add to this a suspension containing one-hundred forty crushed pyrazinamide tablets in 350 mL methylcellulose 1% and 350 mL simple syrup to make 1.7 L suspension. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 60 days refrigerated (preferred) and 45 days at room temperature.</p>\n    <div class=\"reference\">Nahata MC, Morosco RS, and Peritre SP, &ldquo;Stability of Pyrazinamide in Two Suspensions,&rdquo; <i>Am J Health Syst Pharm</i>, 1995, 52(14):1558-60.<span class=\"pubmed-id\">7552903</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215761\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pyrazinamide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $615.49</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215762\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Firizin (BD);</li>\n      <li>Macrozide (CO, LK);</li>\n      <li>Makrozyd (UA);</li>\n      <li>Mide (TW);</li>\n      <li>Neoprazin (BD);</li>\n      <li>Neotibi (ID);</li>\n      <li>P-Zide (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>P.T.B. (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>P.Z.A. (TW);</li>\n      <li>Payzyna (UA);</li>\n      <li>Piraldina (AE, BG, BH, CY, EG, IL, IN, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Pirazinamida (PE);</li>\n      <li>Pirazinamida Prodes (ES);</li>\n      <li>Pirazinid (TR);</li>\n      <li>Pirilene (FR);</li>\n      <li>Pramide (PT);</li>\n      <li>Prazide (VN);</li>\n      <li>Pyrafat (DE, HK, MT);</li>\n      <li>Pyrafate (AT);</li>\n      <li>Pyramide (BD, TH);</li>\n      <li>Pyramin (PH);</li>\n      <li>Pyrazid (PK);</li>\n      <li>Pyrazinamid (HR, HU, PL);</li>\n      <li>Pyrazinamid Lederle (CH);</li>\n      <li>Pyrazinamid &rdquo;Dak&rdquo; (DK);</li>\n      <li>Pyrazinamid &rdquo;Medic&rdquo; (DK);</li>\n      <li>Pyrazinamide (TH);</li>\n      <li>Pyrazine (JO);</li>\n      <li>PZA (CH, QA, SA);</li>\n      <li>PZA-Ciba (IN, SG);</li>\n      <li>PZN-500 (ZW);</li>\n      <li>Rifater (MX);</li>\n      <li>Siramid (ID);</li>\n      <li>TBZet (ID);</li>\n      <li>Tebrazid (BE, CH, LU);</li>\n      <li>Tibicel (ID);</li>\n      <li>Tisamid (CZ, FI);</li>\n      <li>Tubranin (BD);</li>\n      <li>Zcure (PH);</li>\n      <li>Zinamide (AU, GB, NZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis and Pulmonary Infections, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo; <i>Clin Infect Dis</i>, 1995, 21:9-27.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo; <i>Pediatrics</i>, 1992, 89(1):161-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-pediatric-drug-information/abstract-text/1728006/pubmed\" target=\"_blank\" id=\"1728006\">1728006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumberg HM, Burman WJ, Chaisson RE, et al, &quot;American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis,&quot; <i>Am J Respir Crit Care Med</i>, 2003, 167(4):603-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-pediatric-drug-information/abstract-text/12588714/pubmed\" target=\"_blank\" id=\"12588714\">12588714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2016. Available at <a href=\"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0\" target=\"_blank\">https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holdiness MR, &quot;Antituberculosis Drugs and Breast-Feeding,&quot; <i>Arch Intern Med</i>, 1984, 144(9):1888.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-pediatric-drug-information/abstract-text/6548112/pubmed\" target=\"_blank\" id=\"6548112\">6548112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-pediatric-drug-information/abstract-text/27516382/pubmed\" target=\"_blank\" id=\"27516382\">27516382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pyrazinamide tablet (prescribing information]. Atlanta, GA: Mikart, Inc; April 2001.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR, &ldquo;Multidrug Therapy for Tuberculosis in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1990, 9(11):785-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-pediatric-drug-information/abstract-text/2124671/pubmed\" target=\"_blank\" id=\"2124671\">2124671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(6):455-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-pediatric-drug-information/abstract-text/7667049/pubmed\" target=\"_blank\" id=\"7667049\">7667049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Update: Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society/CDC Recommendations - United States, 2001,&rdquo; <i>MMWR Morb Mortal Wkly Rep</i>, 2001, 50(34):733-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrazinamide-pediatric-drug-information/abstract-text/11787580/pubmed\" target=\"_blank\" id=\"11787580\">11787580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Treatment of tuberculosis guidelines. 4th edition. 2010.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12751 Version 83.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F215773\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049590\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049584\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24520318\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F215737\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F49913580\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F12736344\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049592\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F215814\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F215759\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F215741\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299964\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F215746\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F215748\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13375012\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049589\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F215740\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F215758\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F215757\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F215761\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F215762\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12751|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">Pyrazinamide: Drug information</a></li><li><a href=\"topic.htm?path=pyrazinamide-patient-drug-information\" class=\"drug drug_patient\">Pyrazinamide: Patient drug information</a></li></ul></div></div>","javascript":null}